385 related articles for article (PubMed ID: 18364764)
1. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
Bolland M
N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
[No Abstract] [Full Text] [Related]
2. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
Arnold R; Galloway Y; McNicholas A; O'Hallahan J
Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
[TBL] [Abstract][Full Text] [Related]
3. Prevention of group B meningococcal disease by vaccination: a difficult task.
Thomas M
N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
[TBL] [Abstract][Full Text] [Related]
4. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
[TBL] [Abstract][Full Text] [Related]
5. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
[TBL] [Abstract][Full Text] [Related]
6. MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ; Turner N; Petousis-Harris H
Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
Kelly C; Arnold R; Galloway Y; O'Hallahan J
Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
[TBL] [Abstract][Full Text] [Related]
8. The strategy to control New Zealand's epidemic of group B meningococcal disease.
O'Hallahan J; Lennon D; Oster P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
[TBL] [Abstract][Full Text] [Related]
10. New frontiers in meningococcal vaccines.
Anderson AS; Jansen KU; Eiden J
Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
[TBL] [Abstract][Full Text] [Related]
11. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
12. Getting to grips with an epidemic.
Desmond N
Nurs N Z; 2004 Aug; 10(7):2. PubMed ID: 15460638
[No Abstract] [Full Text] [Related]
13. An effective serogroup B meningococcal vaccine.
Domínguez F; Menéndez J; Ochoa R
Vaccine; 2006 Nov; 24(49-50):7025-6. PubMed ID: 16879900
[No Abstract] [Full Text] [Related]
14. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
Pace D
Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
[TBL] [Abstract][Full Text] [Related]
17. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
[No Abstract] [Full Text] [Related]
18. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
[TBL] [Abstract][Full Text] [Related]
19. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
Lennon D
Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
[No Abstract] [Full Text] [Related]
20. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
